VILLA MONASTERO (Symposia)

Attenzione: apre in una nuova finestra.

Symposium 1 Sunday, September 2, 8:00 – 9:45 am
The esophageal mucosa and submucosa
Chairs: R.H. Riddell (Toronto) – M. Upton (Seattle)

Which cells normally exist in the esophageal epithelium? What is their function? R.H. Riddell (Toronto)
What is the function and role of submucosal mucous glands under the esophageal squamous epithelium? J. Sarosiek (El Paso)
Are Dilated Intercellular Spaces (DIS) normal? H.H. Wang (Boston)
Why/when do DIS occur? H. El-Zimaity (Toronto)
Should GEJ biopsies be taken in patients with reflux in the absence of vible BE? J. Abrams (New York)
Do cells in the lamina propria reflect those in the epithelium? H.D. Appelman (Ann Arbor)
How are stem cells identified in the squamous esophagus? M. Upton (Seattle)
Can stem cells be identified in Barrett’s dysplasia? X. Sagaert (Leuven)
What proportion of esophageal stem cells are marrow derived? D. Jain (Yale)
What is the origin and significance of multilayered epithelium? M. Vieth (Bayreuth)

The duplicated muscularis mucosae and its implications

When/why does duplication of the muscularis mucasae happen? K. Takubo (Tokyo)
Are there always 2 layers in BE? – If not, how do we know when are we definitively in the submucosa? C. Streutker (Toronto)
What is the function of the muscularis mucosae? X. Sagaert (Leuven)
Is the metastasizing potential of early carcinoma dependant on extent of spread through the duplicated muscularis mucosae? S. Abraham (Houston)
Does the choice of Endoscopic therapy matter in patients with dysplasia or intramucosal carcinoma R.C. Fitzgerald (Cambridge)
a) For initial therapy?
b) For subsequent therapy

Symposium 2 Sunday, September 2, 10:15 am - 12:00 pm
Immuno-histology in GERD and Barrett's esophagus
Chairs: M. Vieth (Bayreuth) – R. Fiocca (Genoa)
Discussant: N.S. Buttar (Rochester, MN)
Secretary: H. Neumann (Erlangen)

How does the stroma in BE differ from that of the normal esophagus? R.C. Fitzgerald (Cambridge)
How are the epithelial-stromal interactions and signaling pathways altered in association with fibro-muscular anomaly? R.H. Riddell (Toronto)
What is the role of tumor suppressor genes, including p16, p14 and p53 in BE? R. Fiocca (Genoa)
What is the role of proto-oncogenes in BE, including EGF, EGFR, HER2-neu? R.D. Odze (Boston)
How do immuno-histochemical markers differ comparing intestinal/tubular type adenocarcinomas in BE with carcinomas of fundic or signet-cell types? K. Takubo (Tokyo)
Does immuno-histochemistry have a role in grading of neoplasia in BE? As a way to define risk of progression to adenoca? M. Upton (Seattle)
Is there a combination of molecular tests and/or immuno-histochemistry that can improve management compared with H&E stained biopsies and surveillance? H.D. Appelman (Ann Arbor)
What is the role of CDX1 and CDX2 in squamous and cardiac mucosa? A. Bellizzi (Iowa City)
What is the role of desmosomal cadherins and lektins in squamous and cardiac mucosa? H. Neumann (Erlangen)

Symposium 3 Sunday, September 2, 2:30 – 4:15 pm
Leaks – Perforations
Stents for benign / malignant strictures
Chairs: K. Dua (Milwaukee) – P. Siersema (Utrecht)
Discussant: B. Wijnhoven (Rotterdam)

Are there any predictors of response to endotherapy for corrosive strictures? R. Kochhar(Chandigarh)
Should esophageal stents be used for treating benign esophageal strictures? K.S. Dua (Milwaukee)
Are biodegradable stents better alternative to removable stents? P. Siersema (Utrecht)
Esophageal perforation: conservative management, endotherapy or surgery? K.L. Goh (Kuala Lumpur)
Endotherapy for esophageal perforation/leaks: clip, stent, suture, fibrin or combinations? E. DeMoura (Sao Paulo)
What determines the optimal stenting period in benign esophageal strictures/leaks? K.L. Goh (Kuala Lumpur)
Do esophageal leaks due to surgery/instrumentation/ulcers/spontaneous require different treatment options? N. Reddy (Hyderabad)
What strategy to adopt when a fistula of a cervical anastomosis occurs? V.N. Felix (Sao Paulo)
Should esophageal leak/fistula communicating with an infected mediastinal cavity be endoscopically closed? If not, what are the alternatives? If yes, should the cavity be drained percutaneously prior to endotherapy? N.M. Guda (Milwaukee)
How should new fistula secondary to an esophageal stent be treated? E. DeMoura (Sao Paulo)
How can a malignant stricture close to the upper esophageal stricture be palliated? N.M. Guda (Milwaukee)
Palliation of malignant dysphagia: How to choose an esophageal stent. K.S. Dua (Milwaukee)
Are fully covered expandable stents better than partially covered expandable stents? N. Reddy (Hyderabad)
Laser therapy for esophageal strictures M. Häfner (Vienna)
Management of esophageal leaks with intra-thoracic endoscopy and Argon plasma A. Nieponice (Buenos Aires)

Symposium 4 Sunday, September 2, 4:30- 6:15 pm
Benign esophageal stenoses
New tools and concepts for management
Chairs: G. Costamagna (Rome) – L.L. Swanström (Portland)
Discussant: P. Siersema (Utrecht)

Can barium esophagography detect lower esophageal rings or peptic strictures missed on endoscopy? M.S. Levine (Philadelphia)
Are bougie and balloon dilations of benign esophageal strictures similar in efficacy and safety and in what situations one should be preferred over the other? R. Kochhar (Chandigarh)
What can be expected from the novel dilator specifically fitted for UES? P. Belafsky (Los Angeles)
Does steroid injections into refractory benign esophageal strictures delay their recurrence? If yes, why should it not be used routinely for every benign stricture? P. Siersema (Utrecht)
Which esophageal strictures are ideally suited for electrocautery treatment? P. Siersema (Utrecht)
Is endotherapy for benign esophageal strictures and perforations delaying and making surgery more difficult? B. Gayet (Paris)
Do refractory strictures from different etiologies (radiation, corrosive, post-PDT/ESD, anastomotic) respond differently to endotherapy? E. DeMoura (Sao Paulo)
What are the surgical options for benign strictures? K.L. Goh (Kuala Lumpur)
How should we manage esophageal webs? K.S. Dua (Milwaukee)
How should we manage eosinophilic esophagitis-associated strictures? N.M. Guda (Milwaukee)
What is the optimal dose of intra-lesional steroids, the optimal number of sessions of steroid injections, and the best technique of steroid injections? R. Kochhar (Chandigarh)
Can the response to stricture dilation be predicted by EUS or CT characteristics? N. Reddy (Hyderabad)
Should stenoses following severe esophageal burns be treated by esophageal resection or esophageal by-pass? V.N. Felix (Sao Paulo)
The patch esophagoplasty with biological scaffolds for treatment of esophageal strictures. A. Nieponice (Buenos Aires)

Symposium 5 Monday, September 3, 7:45 - 10:00 am
Pediatrics
Chairs: S.R. Jadcherla (Columbus) – S. Nurko (Boston)
Discussant: M. Chehade (New York)

What is the definition of GERD in infants and children? S. Nurko (Boston)
What is the natural history of GER and GERD that starts in infants and children? M. Thomson (Sheffield)
What are the underlying mechanisms that generate symptoms in GERD in children? N. Tipnis (San Diego)
What are the upstream and downstream reflexes that protect against esophageal provocation in infants and children? S.R. Jadcherla (Columbus)
How do you evaluate GERD? R. Rosen (Boston)
What is the best way to determine symptom association with GER events in infants and children? R. Rosen (Boston)
Potential biomarkers for GERD R. Rosen (Boston)
What are the non-pharmacological approaches of managing GER and GERD in infants and children? S.R. Jadcherla (Columbus)
Benefits and risks of pharmacological approaches in managing GER and GERD in infants and children? M. Thomson (Sheffield)
Are the new pediatric GERD guidelines applicable to clinical practice? S. Nurko (Boston)

Symposium 6 Monday, September 3, 10:15 am - 12:00 pm
Eosinophilic esophagitis
Chairs: R.F. Souza (Dallas) – J.E. Richter (Tampa)
Discussant: S.M. Achem (Jacksonville)

What is the definition, prevalence and natural history of EoE? J.E. Richter (Tampa)
What is the role of endoscopy in the evaluation of eosinophilic esophagitis? A.J. Lucendo (Ciudad Real)
Is EoE a food allergy? M. Chehade (New York)
Does a response to PPI therapy distinguish EoE from GERD? R.F. Souza (Dallas)
In vivo optical imaging in EoE? K.K. Wang (Rochester, MN)

Symposium 8 Monday, September 3, 4:30 - 6:15 pm
The role of HRM in clinical practice
Chairs: C.P. Gyawali (St Louis) – R. Tutuian (Bern)
Discussant: J.O. Clarke (Baltimore)

The Chicago classification: how does it help? C.P. Gyawali (St Louis)
HRM vs HRM + Impedance: a further step forward? F. Zerbib (Bordeaux)
Esophageal function: evaluation of reflux mechanisms J. O. Clarke (Baltimore)
HRM in patients before and after surgery R.P. Tatum (Seattle)
HRM in rumination and aerophagia R. Tutuian (Bern)

Symposium 9 Tuesday, September 4, 7:45 - 9:30 am
Non specific motility disorders
The irritable esophagus
Chairs: R.W. McCallum (El Paso) – K. Vega (Oklahoma City)
Discussant: R.I. Rothstein (Lebanon)
Secretary: R. Hejazy (El Paso)

Is there a role for symptom- incomplete bolus clearance correlation in HRIM? (similarly to symptom-reflux correlation) A. Bansal (Kansas City)
Does eosinophilic esophagitis contribute to esophageal chest pain? S.R. Achem (Jacksonville)
What is the relationship between hypertensive LES and vigorous achalasia, a single entity? R.W. McCallum (El Paso)
How does Erythomycin affect esophageal motility? A. Lund-Krarup (Aalborg)
What is the current understanding of spasms localized to the lower esophagus? D. Sifrim (London)
Is presbyesophagus (aging esophagus) a meaningful term and what is its clinical impact D.O. Castell (Charleston)
Does Starlings Law apply to the esophagus? A. Lund-Krarup (Aalborg)
Is the irritable esophagus part of spectrum representing a diffuse disorder of alimentary motility? C.P. Gyawali (St Louis)
What is the impact of HRM on understanding an irritable esophagus? D. Sifrim (London)
Do ethnic and gender based norms impact on diagnosis and treatment of esophageal motor disorders? K. Vega (Oklahoma City)

Symposium 10 Tuesday, September 4, 9:40 – 11:25 am
Chest pain and motility disorders
Chairs: S.R. Achem (Jacksonville) – S.J. Sontag (Chicago)
Discussant: D.O. Castell (Charleston)

What are the specific neural structures that serve as mechano-receptive and thermo-receptive receptors involved in chest pain? M. Kollarik (Baltimore)
What is the origin of chest pain: central, peripheral, or both? Q. Aziz (London)
Health care and epidemiology of chest pain: a global problem? K. Vega (Oklahoma City)
Does barium esophagogram have a role in NCCP? C.L . Canon (Birmingham, AL)
Does normal pH exclude esophageal pain? M. Frazzoni (Modena)
What is the role of High Resolution Manometry in NCCP? J. Clarke (Baltimore)
What is the role of High resolution US in chest pain? R.K. Mittal (San Diego)
What is the meaning of esophageal motility disorders in chest pain? J.E. Richter (Tampa)
Should pH impedance be included in the evaluation of NCCP? M. Frazzoni (Modena)
Are there other treatment modalities for NCCP other than PPIs? S.R. Achem (Jacksonville)
Non-traditional therapy for NCCP S.R. Achem (Jacksonville)
What future research steps should be taken in NCCP? D.O. Castell (Charleston)